At 6.8% CAGR, the APAC Lyophilized Injectable Market is projected to be worth US$ 996.85 million by 2028, says Business Market Insights 

According to Business Market Insights' research, the APAC lyophilized injectable market was valued at US$ 673.33 million in 2022 and is expected to reach US$ 996.85 million by 2028, registering a CAGR of 6.8% from 2022 to 2028. Expansion of pipeline of lyophilized injectable drugs and advancement in lyophilized packaging are the critical factors attributed to the market expansion. 

The continuous research to invent drugs to treat chronic diseases has driven the development of lyophilized injectable drugs in the pharmaceutical industry. Product innovation and strategic activities by critical key players provide the opportunities to penetrate a new therapeutic area/market. About 2,400 injectable products are present in the development pipeline. Drug developers are increasingly interested in lyophilization technique as it can extend the shelf life of small and large molecule drugs. The prevalence of formulation stability challenges for complex APIs and biologics resulted in more pharmaceutical and biopharmaceutical manufacturers turning to lyophilization. The use of lyophilization for pharmaceutical and biopharmaceutical product manufacturing has grown around 13.5% per year over the last five years. Because liquids are the preferred formulation for commercial-scale production of many parenteral products, lyophilization is increasingly essential in bringing liquid products to market. Lyophilization is significant for two reasons increasing numbers of new drug applications and decreasing review times for new drug approvals. More than 3,000 drug candidates are in the pipeline in therapeutic areas where parenteral delivery dominates. Of these 3,000 products, about 2,250 are in pre-clinical development/ Phase I. The remaining candidates, around 750 are in Phase II and Phase III. And this pipeline of lyophilized products will only add to the established list of lyophilized drugs in the upcoming period. Thus, it is expected to augment the lyophilized injectable market. 

On the contrary, growing rate of product recalls hurdles the growth of APAC lyophilized injectable market. 

Based on type of packaging, the APAC lyophilized injectable market is segmented into single-use vials, point-of-care reconstitution, and specialty packaging. The single-use vials segment held 47.0% market share in 2022, amassing US$ 316.40 million. It is projected to garner US$ 463.56 million by 2028 to expand at 6.6% CAGR during 2022-2028. 

Based on type of delivery, the APAC lyophilized injectable market is segmented into prefilled diluent syringes, single-step devices, proprietary reconstitution devices, and multi-step devices. The prefilled diluent syringes segment held 43.7% market share in 2022, amassing US$ 294.48 million. It is projected to garner US$ 448.30 million by 2028 to expand at 7.3% CAGR during 2022-2028. 

Based on indication, the APAC lyophilized injectable market is segmented into metabolic and oncology conditions, infectious diseases, autoimmune diseases, and others. The metabolic and oncology conditions segment held 46.9% market share in 2022, amassing US$ 315.61 million. It is projected to garner US$ 477.41 million by 2028 to expand at 7.1% CAGR during 2022-2028. 

Based on end user, the APAC lyophilized injectable market is segmented into hospitals, ambulatory surgical centers, specialty clinics, and others. The hospitals segment held 47.3% market share in 2022, amassing US$ 318.59 million. It is projected to garner US$ 475.28 million by 2028 to expand at 6.9% CAGR during 2022-2028. 

Based on country, the APAC lyophilized injectable market has been categorized into China, India, Japan, South Korea, Australia, and rest of APAC. Our regional analysis states that China captured 32.9% market share in 2022. It was assessed at US$ 221.38 million in 2022 and is likely to hit US$ 339.59 million by 2028, exhibiting a CAGR of 7.4% during the forecast period. 

Key players dominating the APAC lyophilized injectable market are Aristopharma Ltd.; Baxter; CordenPharma International; Credence MedSystems, Inc.; Curia Global, Inc.; Jubilant HollisterStier (Jubilant Pharma Limited); Nipro; Recipharm AB; S.G. Biopharm Pvt. Ltd.; and Vetter Pharma among others. 

In Oct 2020, Credence MedSystems and SCHOTT AG have formed a collaboration for the application of Credence Companion technology with SCHOTT's pre-fillable syriQ glass and SCHOTT TOPPAC polymer syringe systems. The two companies will work together to integrate the technologies and provide the pharmaceutical industry with an innovative and differentiated offering for the delivery of injectable medications via prefilled syringes. 

In Jan 2021, Novartis has invested in Credence, confirming its interest in employing Credence technology for its injectable medicines. The investment is geared towards supporting Credence's ramp-up of manufacturing capacity for its innovative drug delivery systems and enabling commercial supply of Credence devices to the pharmaceutical market. 

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com